Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry

Bhandari, S.; Squirrell, David; Nguyen, Vuong; Wang, Nancy; Wells, Jane M.; Tan, Terence; Barnes, Rachel; Barry, Richard C.; Barthelmes, Daniel; Gillies, Mark C

doi:10.1038/s41433-021-01509-x

Cited by 10 publications

(7 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In clinical practice, poor compliance leading to inadequate injection frequency is another important cause of the poor response. The frequency of injections in our study (8 ± 3) was similar to previous RCTs for DME [ 31 , 32 ] and slightly higher than in other real-world studies [ 33 , 34 ]; therefore, it is unlikely that undertreatment was a confounding factor. Furthermore, as the genomic control inflation factor λ was 1.000, our analyses suitably controlled for population stratification and cryptic relatedness.…”

Section: Discussionsupporting

confidence: 87%

Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema

Gurung

FitzGerald

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

Intraocular anti-vascular endothelial growth factor (VEGF) therapies are the front-line treatment for diabetic macular edema (DME); however, treatment response varies widely. This study aimed to identify genetic determinants associated with anti-VEGF treatment response in DME. We performed a genome-wide association study on 220 Australian patients with DME treated with anti-VEGF therapy, genotyped on the Illumina Global Screening Array, and imputed to the Haplotype Reference Consortium panel. The primary outcome measures were changes in central macular thickness (CMT in microns) and best-corrected visual acuity (BCVA in ETDRS letters) after 12 months. Association between single nucleotide polymorphism (SNP) genotypes and DME outcomes were evaluated by linear regression, adjusting for the first three principal components, age, baseline CMT/BCVA, duration of diabetic retinopathy, and HbA1c. Two loci reached genome-wide significance (p < 5 × 10−8) for association with increased CMT: a single SNP on chromosome 6 near CASC15 (rs78466540, p = 1.16 × 10−9) and a locus on chromosome 12 near RP11-116D17.1 (top SNP rs11614480, p = 2.69 × 10−8). Four loci were significantly associated with reduction in BCVA: two loci on chromosome 11, downstream of NTM (top SNP rs148980760, p = 5.30 × 10−9) and intronic in RP11-744N12.3 (top SNP rs57801753, p = 1.71 × 10−8); one near PGAM1P1 on chromosome 5 (rs187876551, p = 1.52 × 10−8); and one near TBC1D32 on chromosome 6 (rs118074968, p = 4.94 × 10−8). In silico investigations of each locus identified multiple expression quantitative trait loci and potentially relevant candidate genes warranting further analysis. Thus, we identified multiple genetic loci predicting treatment outcomes for anti-VEGF therapies in DME. This work may potentially lead to managing DME using personalized treatment approaches.

show abstract

Section: Discussionsupporting

confidence: 87%

Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema

Gurung

FitzGerald

Liu

et al. 2022

IJMS

View full text Add to dashboard Cite

show abstract

“…Reasons for discontinuation were not recorded in most cases-we have previously reported that most people who are lost to follow-up in our database because of causes unrelated to poor outcomes, such as patient death or going to another doctor, although some do drop out because of poor outcomes. [26][27][28] Including noncompleters in our analysis using longitudinal mixed models is an appropriate method to deal with dropouts provided the data are missing at random. 29 The assumption of missing at random is reasonable provided that the 12-month outcomes for noncompleters can be reasonably inferred based on their visual acuity measurements leading up to dropout and they did not experience any unobserved deviations from their observed trajectory.…”

Section: Discussionmentioning

confidence: 99%

Association Between Anatomical and Clinical Outcomes of Neovascular Age-Related Macular Degeneration Treated With Antivascular Endothelial Growth Factor

Nguyen

Puzo

Sánchez‐Monroy

et al. 2020

Retina

Self Cite

View full text Add to dashboard Cite

show abstract

“…The DME treatment has been revolutionized by the progress in anti-VEGF injections, with a well-documented recovery in BCVA and a reduction of CMT, was con rmed by several RCTs [16,17]. Nevertheless, there are only a few studies in real-life setting comparing IVR and IVA in DME patients, while most of them have included low number of patients [18][19][20].…”

Section: Discussionmentioning

confidence: 99%

“…Change in mean BCVA at month 6 was 0.03 vs 0.09 logMAR in IVR and IVA groups, respectively and they reported that the effectiveness of IVA in improving the BCVA might be better than IVR. In the study of Bhandari et al [20] which includes 303 treatment naïve eyes (136 IVR vs 167 IVA) of 228 patients with DME who completed 12 months follow-up period, authors founded that both IVR and IVA were effective for DME over 12 months, with a ibercept having somewhat better anatomical outcomes (change in CMT was − 126 m vs -89 m, p < 0.01). Larger BCVA gains were observed in IVA group when the initial BCVA was ≤ 0.3 logMAR (change in BCVA was 10.6 letters vs 7.6 letters, p = 0.01).…”

Section: Discussionmentioning

confidence: 99%

Three Year Outcomes of Intravitreal Ranibizumab and Aflibercept Treatment of Patients with Diabetic Macular Edema in a Real-World Setting

Akbaş

Alagöz

Çakmak

et al. 2021

Preprint

View full text Add to dashboard Cite

PurposeTo evaluate and compare the functional and anatomical outcomes of intravitreal ranibizumab (IVR) and aflibercept (IVA) treatments in patients with diabetic macular edema (DME).MethodsFour hundred three eyes of 235 naïve patients who underwent IVR or IVA treatment for diabetic macular edema and followed up to 36 months included in this retrospective, real-life study. All patients underwent 3 loading doses and followed up with a PRN regimen. Best corrected visual acuity (BCVA) and central macular thickness (CMT) were measured at baseline, year 1, 2 and 3. ResultsThere were 198 eyes in IVR group and 205 eyes in IVA group. The changes in mean BCVA were 0.09±0.32 vs 0.17±0.41 logMAR (p=0.042) at year 1, 0.09±0.37 vs 0.12±0.45 logMAR (p=0.512) at year 2 and 0.13± 0.36 vs 0.15±0.48 logMAR (p=0.824) at year 3 in IVA and IVR groups, respectively. The baseline mean BCVA were lower (p=0.004) in IVA group. In terms of CMT changes, there were no differences between groups. ConclusionAt year 1, change in mean BCVA was statistically significantly higher in IVA group, however this difference did not persist at year 2 and 3. Both ranibizumab and aflibercept treatments achieved a good long-term visual and anatomical response in DME patients.

show abstract

Bevacizumab for diabetic macular oedema: one-year treatment outcomes from the Fight Retinal Blindness! Registry

Cited by 10 publications

References 24 publications

Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema

Identifying Genetic Biomarkers Predicting Response to Anti-Vascular Endothelial Growth Factor Injections in Diabetic Macular Edema

Association Between Anatomical and Clinical Outcomes of Neovascular Age-Related Macular Degeneration Treated With Antivascular Endothelial Growth Factor

Three Year Outcomes of Intravitreal Ranibizumab and Aflibercept Treatment of Patients with Diabetic Macular Edema in a Real-World Setting

Contact Info

Product

Resources

About